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Summary
Irritable bowel syndrome (IBS) is the most common chronic gastrointestinal (GI) disorder,
affecting about 20% of the world’s population. Chronic abdominal pain or discomfort relieved
by defecation and associated with altered bowel habits are the mainstay in diagnosis. The
pathophysiology of IBS remains unknown. This biopsychosocial disorder involves dysregula-
tion of the nervous system, altered intestinal motility, and increased visceral sensitivity. All of
these result from dysregulation of the bidirectional communication between the gut with its
enteric nervous system and the brain (the brain-gut axis), modulated by various psychosocial
and environmental factors (e.g. infection, inflammation). Numerous neurotransmitters are
found in the brain and gut that regulate GI activities, including 5-hydroxytryptamine (5-HT,
serotonin) and its 5-HT3 and 5-HT4 receptors. The current approach to IBS patients is based
on a positive diagnosis of the symptom complex, exclusion of underlying organic disease, and
institution of a therapeutic trial. Traditional symptomatic treatment has included antidiar-
rheals, laxatives and bulking agents/fiber, low-dose tricyclic antidepressants, antispasmodics
for pain, and ‘alternative’ therapies (e.g. psychotherapy, hypnotherapy). The scientific evi-
dence supporting this therapy is limited. Novel approaches include visceral analgesics and
serotonin agonists and antagonists. In patients with severe diarrhea, 5-HT3 receptor antago-
nists (e.g. alosetron) and selective M3-type anticholinergics are indicated, in constipation 5-
HT4 agonists (e.g. tegaserod), and in pain alfa2-adrenergics (e.g. clonidine), cholecystokinin
antagonists, kappa-opioid agonists (e.g. fedotozine), and neurokinin antagonists; some of
these agents are still being investigated. Understanding the brain-gut axis is crucial in the
development of effective therapies for IBS.
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BACKGROUND
Irritable bowel syndrome (IBS) is a chronic disorder of
the gastrointestinal (GI) function characterized by con-
tinuous or remittent abdominal pain and is associated
with altered bowel habits, diarrhea or constipation or
both, and bloating [1]. The disorder cannot be explained
by specific pathophysiologic mechanisms, or structural
or known biochemical abnormalities. IBS symptoms are
multi-determined and are generated from dysregulation
at multiple levels of the brain-gut axis (BGA). They are
manifested by abdominal motor reactivity to various
stimuli and low sensation and pain thresholds. Psycho-
social factors also have an important role in modulating
both the disease experience and clinical outcome. IBS is
highly prevalent and can be associated with significant
emotional distress, impaired health-related quality of
life, disability, and high health care costs [2,3].
IBS is one of the most common clinical problems
encountered by the general practitioners and gastroen-
terologists [4,5]. Approximately 10–15% of the general
population has IBS, and more than 40% of IBS patients
have such frequent and severe symptoms as to lead to a
reduction in quality of life and result in numerous visits
to physicians. The economic impact of IBS is large [5].
The estimated health care costs of IBS in the United
States are very high, with $19.2 billion annual indirect
costs (e.g. work absenteeism, reduced productivity) and
$1.6 billion direct medical expenses (e.g. visits to health-
care providers, diagnostic workups, treatment) [2,5,6].
There are no specific laboratory tests or physical mark-
ers that are pathognomonic for IBS. Therefore the
diagnosis is based on symptoms and clinical features as
well as an absence of any alarm indicators [3,7,8]. In
1978, Manning and associates established six criteria to
distinguish IBS from organic bowel disease. Talley and
co-workers showed that the Manning criteria are sensi-
tive in 58% and specific in 74% of cases in discriminat-
ing IBS from organic GI diseases [9,10]. These criteria
were updated in 1999, and the Rome criteria have come
to be accepted as the state-of-the-art criteria for research
studies and clinical practice [3]. According to the Rome
criteria, IBS is defined on the basis of abdominal pain
and alteration of bowel habits. The symptoms are used
to differentiate three subgroups of patients: those with
constipation-predominant IBS, those with diarrhea-pre-
dominant, and those with alternating bowel movements
[11]. The Rome criteria have a positive predictive value
of approximately 98% and additional diagnostic tests
have a yield of 2% or less [7]. However, many authors
suggest that the diagnostic criteria for IBS need further
validation [10,12].
IBS is heterogeneous in nature, and patients experience
not only abdominal discomfort and bowel problems, but
sometimes many other symptoms, including heartburn,
back pain, headache, urinary frequency, muscle pains,
menorrhagia, dyspareunia, anxiety, and depression [1].
It is essential to differentiate between organic and func-
tional causes of symptoms. An organic pathology may be
suspected in a patient with any of the so-called alarm fea-
tures: beginning of symptoms at an age over 50 years,
progression or worsening of symptoms without periods
of relief, nighttime symptoms, rectal bleeding, anemia,
hypoalbuminemia, anorexia, unexplained weight loss,
recurrent vomiting, family history of colon cancer,
abnormal physical findings (e.g. mass), and extraintesti-
nal manifestations as seen in inflammatory bowel disease
[8]. The presence of any of these features is usually an
indication for further investigations (Table 1) [10].
EPIDEMIOLOGY
Epidemiologic studies are difficult to interpret because
there is a lack of clear pathologic features of IBS [1].
The investigated population may vary according to the
nature and interpretation of the diagnostic criteria. IBS
seems to be as common in American and Asian as it is in
European countries. Prevalence seems to be similar in
whites, blacks, and Hispanics [2]. The overall prevalence
from questionnaire studies is 2.9%, but population-
based studies in the USA estimate the prevalence of IBS
between 5% and 25% [2,3,5]. The precise incidence of
IBS is unclear, but it has been estimated at 1–2% per
year [5]. Although the majority of people with IBS do
not consult a physician, approximately 10–25% of
patients seek family practice and 1% is referred to a gas-
troenterologist [6,14]. The prevalence of IBS is 3–4
times greater in women than men, and female patients
seem to have more frequent and severe symptoms and
they seek health care more often [1–3].
IBS can affect people at any age, but the prevalence of
IBS declines with age [15]. Approximately 50% of peo-
ple with IBS report beginning of symptoms before the
age of 35 [3]. Traditionally, IBS is not diagnosed in peo-
ple after the age of 60, when organic diseases of the gut
become more frequent [1,3,5,15].
IBS does not increase mortality or the risk of inflamma-
tory bowel disease or cancer. Patients with IBS who seek
medical attention are more disturbed psychologically,
more likely to have abnormal personality profiles, are
more concerned about their health and fearful of illness
[5].
PATHOPHYSIOLOGY
The pathophysiology of IBS is heterogeneous and not
fully elucidated. Recent studies have led to a greater
understanding of the association between the gut and
CNS. Currently, the model for IBS incorporates
enhanced motility, abnormal sensation, and autonomic
reactivity modulated by CNS-enteric nervous system
(ENS) interaction, or the BGA. Moreover, enteric infec-
tion, immune activation, and inflammation of the colonic
mucosa as well as the enteric neuro-muscular apparatus
play a role in the pathophysiology of IBS [4,16].
IBS is recognized as a biopsychosocial disease in which
several major mechanisms interact, including enhanced
visceral sensation (visceral hypersensation), central per-
ception of visceral events, abnormal intestinal motility,
and abnormal psychosocial factors [3,4].
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DYSREGULATION OF THE NERVOUS SYSTEM
The GI tract is innervated by five different classes of
neurons: intrinsic enteric, vagal afferent, spinal afferent,
parasympathetic efferent, and sympathetic efferent [17].
Each aspect of digestive activity is under the regulatory
influence of neurons, among which the ENS plays the
most important role [17,18].
The ENS, also called the ‘little brain’ of the gut, func-
tions independently of the CNS [17,19]. It controls GI
motility and secretion and is involved in visceral sensa-
tion. The ENS has been shown to exert an important
role in the regulation of several intestinal mucosal func-
tions, including mucosal blood flow, regulation of
epithelial permeability, organization and cell prolifera-
tion (20). All of these functions contribute to the mainte-
nance of the intestinal barrier [20].
Brain-gut bidirectional communication plays a prominent
role in the modulation of gut function. Signals from sen-
sory sources (e.g. sound, sight, smell, somatic and visceral
sensations) to the brain play a role in reflex regulation and
in the modulation of mood states [2]. These inputs are
modified by memory, cognition and affect, then integrat-
ed within neural circuits in the CNS, spinal cord, auto-
nomic nervous system (ANS), and ENS [2,3,18]. These
inputs can have physiologic effects, such as changes in
motility, secretion, immune function, and blood flow with-
in the GI tract [2,3]. The emotional motor system in the
brain is a revised name for the limbic system, and some
paralimbic structures (including the medial prefrontal
cortex, amygdale, and hypothalamus) communicate emo-
tional changes via the ANS to the gut [2]. The CNS is also
essential in the perception of events occurring within the
gut. Alteration at any level can lead to altered sensation,
dysmotility, or psychological distress. In IBS, dysregula-
tion has two components. There may be dysregulation of
motor nerves regulating GI smooth muscle contraction,
resulting in abnormal intestinal motility, or there may be
dysregulation of the sensory nerves linking intestinal
receptors and nerve endings to the CNS, resulting in
enhanced awareness and hypersensitivity to abdominal
distension, contraction, and discomfort [2].
The activation of the modulatory systems is dependent
on peripheral and central events. Stress, anxiety, or
recall of some memories can enhance the perception of
painful events, whereas distraction, hypnosis, and relax-
ation can decrease perceptual sensitivity [2]. Stress-
induced visceral hyperalgesia may be an important
mediator of visceral hypersensitivity in IBS patients [2].
Imaging studies of regional central blood flow during
rectal distention give us evidence of the importance of
altered brain perception of visceral stimuli [8,16]. Using
distal colonic stimulation in IBS patients, a greater acti-
vation of the midcingulate cortex, a brain region con-
cerned with attentional processes and response selec-
tion, was shown. This region, modulated by hypnotic
suggestion, was associated with changes in the subjective
unpleasantness of a somatic pain stimulus in another
study [2]. Hypnosis is likely to modulate attentional
mechanisms (including the midcingulate cortex), and
relaxation exercises involving deep breathing tech-
niques may alter vagal afferent input to the brain [2].
Centrally targeted medications, such as anxiolytics, low
dose tricyclic antidepressants, and corticotropin releas-
ing factor 1R (CRF-1R) antagonists, all involve inhibito-
ry effects on the responsiveness of the emotional motor
system and provide options for future therapeutic inves-
tigations [2].
ABNORMAL INTESTINAL MOTILITY
About 25–75% of patients with IBS have disturbances in
GI motility [2]. Many studies identified abnormal pat-
terns of contractile activity and electrical activity in the
colon of patients with IBS. Patients with diarrhea-pre-
dominant IBS have a greater number of fast colonic
contractions and propagate contractions with subse-
quent accelerated transit [3]. Patients with constipation-
predominant IBS have a decreased number of fast
colonic and propagated contractions, and fewer high-
amplitude propagated contractions with slowed whole-
gut transit [3]. Patients with abdominal pain have signif-
icantly more ‘cluster’ contractions, which are groups of
brief propagated intestinal contractions of higher ampli-
tude than in healthy controls [21].
Manning criteria Rome II criteria
Onset of pain associated with more frequent bowel movements
Onset of pain associated with looser bowel movements
Pain relieved by defecation
Visible abdominal distention
Subjective sensation of incomplete rectal evacuation (more than 25%
of the time)
Passage of mucus (mucorrhea; more than 25% of the time)
At least 12 weeks, which need not be consecutive, in the preceding 12
months of abdominal discomfort or pain that has 2 of 3 features:
1. Relieved with defecation; and/or
2. Onset associated with a change in frequency of stool; and/or
3. Onset associated with a change in form (appearance) of stool
Symptoms that cumulatively support the diagnosis of IBS:
1. Abnormal stool frequency (greater than 3 bowel movements per day
or less than 3 bowel movements per week)
2. Abnormal stool form (lumpy/hard or loose/watery)
3. Abnormal stool passage (straining, urgency or feeling of incomplete
rectal evacuation)
4. Passage of mucus
5. Bloating or feeling of abdominal distention
Table 1. The Manning and Rome II diagnostic criteria for irritable bowel syndrome [13,14].
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Motility abnormalities may interact with low sensory
thresholds to produce symptoms: delayed transit of gas
causes greater abdominal perception in IBS,  and IBS
patients are more likely than healthy controls to perceive
the occurrence of normal migrating motor complexes [2].
The factors controlling GI function may be exacerbated
by environmental factors such as stress, provocative stim-
uli including cholecystokinin, neostigmine, corticotropin-
releasing hormone, and intestinal factors such as the pres-
ence of food in the gut or bile acids [1].Irregular sponta-
neous contractions may result in distension of the gut.
Hyperactivity of the enteric nerves in patients with IBS
may play a role in disturbance of GI motility [3]. Several
neurotransmitters are involved in the regulation of
motility and pain in the gut, including 5-hydroxytrypta-
mine (5-HT; serotonin) [18].
VISCERAL HYPERSENSITIVITY
It was first reported by Ritchie in 1973 that IBS patients
have pain at lower volumes and pressures when a balloon
is inflated in the bowel [2]. Other authors showed that the
threshold of reporting pain is below the normal range in
50–70% of IBS patients [2]. The patients are more sensi-
tive to normal intestinal activity and distensions of the
colon [1]. Diarrhea-predominant IBS patients exhibit
lower thresholds for sensation of gas, stool, and discom-
fort in the distal colon, and urgency is developed at lower
volumes of rectal balloon distention [3]. Patients with con-
stipation-predominant IBS develop discomfort at greater
distention volumes than healthy controls [3].
The enhanced pain sensitivity in IBS patients is related
to increased visceral sensitivity. Visceral hypersensitivity
is recognized by many investigators as a biological mark-
er for IBS [2–4]. The mechanisms of visceral hypersen-
sitivity include increased end-organ sensitivity with
recruitment of silent nociceptors, spinal hyperexcitabili-
ty with activation of nitric oxide and other neurotrans-
mitters via endogenous modulation of caudal nocicep-
tive transmission, and development of long-term hyper-
algesia due to the development of neuroplasticity (per-
manent or semipermanent changes in neural response
to chronic or recurrent visceral stimulation) [3].
CHANGES IN SENSORY ACTIVITY
The CNS responds to impulses from all parts of the body
by initiating appropriate biochemical and biophysical
actions in target organs and tissues [3]. In patients with
IBS, some of the CNS pathways may be hyperactive and
inappropriately exaggerate the sensation of abdominal
activity and pain [3]. This is probably caused by an increase
in the number of nociceptors in the abdomen, overactive
nociceptor nerves in the spinal cord following repeated
distention of the colon, and psychological factors [3].
PSYCHOSOCIAL FACTORS
Psychological and psychiatric problems such as somatiza-
tion, anxiety, hypochondriasis, depression, and phobia
are common in patients with IBS [3,4]. Psychological
stress and anxiety may exacerbate GI symptoms in nor-
mal as well as in IBS patients [3]. It is well known that
IBS reduces quality of life, which may have psychological
consequences [3]. About 50% of patients with IBS have
these problems at the time of diagnosis [3]. Psychological
and sociocultural factors in patients with IBS influence
not only the illness experience, but also the treatment
outcome. Psychosocial factors include: a history of emo-
tional, sexual, or physical abuse, stressful life events,
chronic social stress, or anxiety disorder, and maladap-
tive coping style. Some of these psychosocial influences
may occur early in life [2].
POSTINFECTIOUS IBS
The relationship between enteric infection and alteration
in gut immune function as well as the subsequent devel-
opment of IBS is well documented [1,2,21,22]. A group
of IBS patients develops the IBS symptoms with the
onset of gastroenteritis (so-called postinfectious IBS; PI-
IBS). In prospective studies, IBS symptoms were found
in 20–30% of patients who had recovered from a bacteri-
al gastroenteritis [2]. There are several risk factors of PI-
IBS, including: female gender, severe and long acute
gastroenteritis, and the presence of significant psycho-
logical disturbances occurring around the time of the
infection [1,2,4,23]. It is believed that gastroenteritis may
sensitize the bowel, but the development of IBS depends
on the coexistence of psychosocial factors [1].
Many studies have shown that patients with PI-IBS have
a variety of functional and morphological alterations,
including changes in gut motility, epithelial function,
increase in colonic enterochromaffin cells, lymphocytes,
mast cells, increased cellularity of lamina propria, lym-
phocytic infiltrates of the myenteric plexus, and
increased nitric oxide synthetase in colonic mucosa
[2,4,22]. In addition, patients with PI-IBS were found to
have evidence of increased expression of interleukin 1
messenger RNA and an increase in CD3+ lymphocytes
in mucosal biopsy specimens [2,24].
There is a growing body of evidence that inflammation
and immune activation contribute to at least a subset of
IBS patients. Chadwick et al. showed evidence of
immune activation in examined mucosa biopsies from
almost 90% of IBS patients who met Rome criteria [24].
Half of these patients had a normal mucosa appearance
on routine examination and the remainder had
increased cellularity of the mucosa and submucosa with
a diagnosis of microscopic colitis. Findings of increased
intraepithelial lymphocytes, CD3+ cells, nature killer,
and mast cells contribute to the growing body of litera-
ture demonstrating an increased inflammatory cell pres-
ence in the colonic mucosa of certain IBS patients
[2,25]. In patients with PI-IBS, the T cell subgroups
remain increased for more than a year after infection.
This may reflect immune activation by luminal antigen
because of increased intestinal permeability in these
patients. Therefore, it is believed that inflammatory
stimuli may induce a hyperalgesic state and alter motor
function in patients with IBS. The substances that medi-
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ate these changes are not fully understood, but there is
growing recognition of the role of serotonin as a sensi-
tizing agent [26].
Recent studies have shown that there is interaction
between the ENS and the immune system, especially in
relation to functional bowel disorders [19]. It was also
shown that ENS nerves play a role in gut mucosa
integrity and restitution [19]. Thus, alteration in gut
immune function may play a role in IBS, but correlation
of IBS symptoms with these changes has not been estab-
lished. Moreover, the majority of patients with gastroen-
teritis do not develop PI-IBS. It is also interesting that
the prevalence of IBS is not higher in countries with
high incidences of GI infections. Therefore, further
studies are needed to determine which vulnerability fac-
tors play a role in the development of PI-IBS. In addi-
tion, psychological distress seems to be an important
cofactor in determining who retains symptoms after an
enteric infection.
THE BRAIN-GUT AXIS
There is relationship between the function of the CSN
and the intestines via the specialized ENS of the gut.
The ENS independently controls gut function, the
migrating motor complex, and peristalsis, and is con-
stantly monitored and modified by both vagal and sym-
pathetic extrinsic nerves [3].
The brain and gut reciprocally affect the experience
and regulation of visceral pain. Visceral signals are
transmitted via ascending pathways to the midbrain,
thalamus, and cortex. The somatosensory cortex
receives somatotypic information about the location and
intensity of pain and the limbic system (anterior cingu-
lated cortex, insula, medial thalamus) is involved with
the affective and motivational component of pain [27].
The limbic system can modulate the pain experience via
activation of descending regulatory pathways [27].
Therefore, normal GI function results from an integra-
tion of intestinal motor, sensory, autonomic, and CNS
activity, which interact through bidirectional parallel
circuits. The BGA links visceral afferent sensations and
intestinal motor function with higher cortical centers
that modulate and modify their activity.
Neural transmission within the gut (ENS) and brain
(CNS) is controlled by numerous neurotransmitters and
neuromodulatory peptides, including CRF, vasoactive
intestinal peptide (VIP), serotonin and its congeners,
calcitonin gene-related polypeptide (CGRP), acetyl-
choline, substance P, nitric oxide, cholecystokinin, and
the enkephalins [18,27,28].
Serotonin (5-HT) is a major neurotransmitter in the GI
tract. It plays a key role in the pathogenesis of IBS. In
particular, two 5-HT receptors, 5-HT3 and 5-HT4,
appear to be very important in the control of GI func-
tion. They are involved in visceral sensation and in the
function of the ENS, including secretion and motility.
The gut contains over 95% of the body’s 5-HT, and the
concentration of 5-HT in the bowel is higher than that
in the brain [3]. 5-HT is a signaling molecule which par-
ticipates in mucosal sensory transduction [3,18]. 5-HT
stimulates by varied receptors in the GI tract both vagal
and enteric afferent nerve fibers [3]. Before activation of
extrinsic afferent nerves, specific stimuli arising within
the lumen of the GI tract may activate specialized cells
present in the mucosa [18]. The most important are
enterochromaffin cells, which act as principal sensory
transducers. 5-HT released from these cells acts directly
on vagal extrinsic afferent nerves in the mucosa
through activation of 5-HT3 receptors exposed on the
nerve terminal [18].
As a neurotransmitter in the ENS, 5-HT plays a role in
initiating responses as diverse as nausea, vomiting,
intestinal secretion, and the peristaltic reflex [3].
Therefore, the antagonism of the 5-HT receptors is use-
ful in the therapy of functional bowel diseases [3].
DIAGNOSIS AND TREATMENT
The diagnosis of IBS is based on the identification of
symptoms and the exclusion of organic diseases. The
Rome II criteria are usually used in clinical practice to
assess the patient’s symptoms (Table 1). Physical exami-
nation and several initial investigations are needed to
exclude organic, metabolic, or infectious diseases (Table
2). A careful search for psychosocial factors, stress, and
physical or sexual abuse are also important.
The first and crucial step in the treatment of patients
with IBS is establishing an effective and positive physi-
cian-patient relationship [1,5,10]. Therapy is based on
the dominant symptom (IBS subtype). Therapeutic
options include dietary modifications, counseling, med-
ications, and psychological treatments thoroughly
described by many authors [1–5,29-35]. Fiber and bulk-
ing agents may help constipation, but the evidence that
they are efficacious in IBS is equivocal. These agents are
frequently prescribed as first-line drugs for IBS regard-
less of the primary bowel disturbance [30]. Laxatives
have no established value in IBS, but are often taken by
patients with constipation predominant IBS [5].
Antispasmodics are usually prescribed for abdominal
pain [5,29]. Low doses of tricyclic antidepressants may
be effective, but side effects and patient concerns
regarding use of a centrally acting agent for depression
remain limitations [29,30]. Other groups of antidepres-
sants and selective serotonin reuptake inhibitors are of
uncertain efficacy in IBS. Loperamide, a mu-opioid
agonist, is useful for diarrhea but not for pain in IBS.
Complete medical history
Physical examination
Initial laboratory analyses: complete blood cell count, electrolytes,
blood urea nitrogen, creatinine, albumin, C-reactive protein
or erythrocyte sedimentation rate
Thyroid-stimulating hormoneLook for alarm symptoms indicating
the presence of organic disease
If yes: additional workup; if no: initiate treatment
Table 2. Initial workup in patients suspected of having IBS [10].
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The precise underlying pathophysiology of IBS remains
unknown. However, disturbances in the BGA involving
the CNS and the ENS have emerged as an underlying
concept for IBS [31]. In this regard, the above-men-
tioned conventional therapy has been recognized as
unsatisfactory for many patients with IBS [5,31].
Therefore, novel neuroenteric modulatory compounds
have been introduced for clinical use [2,5]. Novel
approaches include visceral analgesics, specifically drugs
interacting with the 5-HT receptors. Serotonin agonists
and antagonists have been demonstrated to be of bene-
fit in some patients in the treatment of IBS. Both
reduce visceral sensitivity and change motor activity
[2,30]. In patients with severe diarrhea, 5-HT3 receptor
antagonists (alosetron), which retard small bowel and
colonic transit and relieve pain, are indicated. However,
the indication for alosetron has been restricted and it is
used in several countries only for women with severe
diarrhea-predominant IBS who have had symptoms for
at least 6 months and who have failed to respond to
conventional therapy [31]. In patients with constipation,
5-HT4 agonists (e.g. tegaserod, prucalopride, which
accelerate small bowel and colonic transit) are of clinical
value. Tegaserod is the first selective 5-HT4 receptor
partial agonist to be approved for the treatment of con-
stipation-predominant IBS. It is active against multiple
IBS symptoms; it stimulates gut motility and reduces
visceral sensitivity and pain. The drug does not cure
IBS and was not designed to treat the diarrhea-predom-
inant version [32]. Tegaserod is available in the United
States and other countries for use in women with IBS
whose primary bowel symptom is constipation; its effica-
cy in men and in those with alternating bowel habits has
not been established. In patients with IBS and pain, sev-
eral groups of drugs are helpful, including alfa2-adren-
ergic agonists (e.g. clonidine, which reduces tone and
pain sensation), cholecystokinin antagonists, kappa-opi-
oid agonists (e.g. fedotozine), and neurokinin antago-
nists (reduce visceral sensation, constipation, bloating),
but some of these agents are still being investigated
[2,5,33]. In patients with IBS and abdominal pain, sev-
eral new groups of drugs are obtainable (Table 3)
[5,30,31,34,35]. Progress in our understanding of the
role of the BGA disturbances is a key to the develop-
ment of new and effective therapies for IBS [5].
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